Genfit SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Genfit SA Announces Results of GFT505-111-7 Study
Genfit SA announced the results of the GFT505-111-7 study demonstrating the safety and efficacy of increasing doses of GFT505 up to a dose three-fold higher than the current therapeutic dose of 80 mg/d. No serious adverse event was reported in this study. Compared to placebo, there were fewer undesirable effects in GFT505-treated patients. Moreover, no adverse event was reported in the subjects treated at the dose of 240 mg/d. In all groups, biochemical safety markers were unchanged. In particular, renal safety markers (creatinine) and hematological parameters were unchanged by GFT505 treatment.
Latest Developments for Genfit SA
- Genfit SA Announces Share Repurchase Program
- Genfit SA Announces Publication of GFT505-210-6 Clinical Study Data in Diabetes Care
- Genfit SA Announces Data Reporting the Efficacy and Mechanism of Action of GFT505 in Different Animal Models of NASH
- Genfit SA Announces Results of Phase II Clinical Studies Showing that GFT505 Reduces the Risk of Cardiovascular Events Through its Action on Remnant Cholesterol
- Share this
- Digg this